China PV Audits: Key Insights for Managing Local Representatives in China
In 2019, the Drug Administration Law in China fully implemented the Marketing Authorization Holder (MAH) system. In 2020, the China National Medical Products Administration (NMPA), the counterpart of the US FDA and EU EMA, issued the “Interim Provisions on the Management of Local Representatives of Overseas Drug Marketing Authorization Holders (Draft for Comments).” This article […]